Has Dawn Tingwald received payments from drug or device companies?

Yes. Drug and device makers reported $1,014 in general payments to Dawn Tingwald across 48 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dawn Tingwald did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dawn Tingwald come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dawn Tingwald

Family · Ogden, IANPI 1083169270

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $360 and has fallen 51.2% since, to $176 in 2025.

$1,014in general payments, 2019–2025

Across 48 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alkermes, Inc.$129
AbbVie$99
Pfizer$96
Amgen$95
Johnson & Johnson$77
Novo Nordisk$66
plus $452 from 15 others

What the payments were for

Food & beverage$1,014100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alkermes, Inc.	2	$129
AbbVie	5	$99
Pfizer	6	$96
Amgen	4	$95
Johnson & Johnson	4	$77
Novo Nordisk	5	$66
Insulet Corporation	2	$57
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$55
Sanofi-aventis U.S. LLC	2	$43
Biohaven Pharmaceuticals, Inc.	2	$41
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$40
Abbott	1	$40
E.r. Squibb & Sons, L.L.C.	2	$38
Neurocrine Biosciences, Inc.	1	$32
Bayer	1	$19
Boehringer Ingelheim	1	$17
Takeda Pharmaceuticals U.S.A., Inc.	1	$16
Mylan Specialty L.p.	1	$15
Astellas Pharma US Inc	1	$14
Sunovion Pharmaceuticals Inc.	1	$12
Dexcom, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ARISTADA$462
ARISTADA INITIO$115

How this compares

$1,014 in reported general payments places this provider in the 80th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	82	$85,657
OzempicSemaglutide	54	$61,984
EliquisApixaban	78	$55,924
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	60	$43,015
Soliqua 100-33Insulin Glargine/Lixisenatide	20	$24,772
Stiolto RespimatTiotropium Br/Olodaterol Hcl	34	$19,861
XareltoRivaroxaban	31	$18,794
Tresiba Flextouch U-200Insulin Degludec	19	$13,002
Spiriva RespimatTiotropium Bromide	16	$9,289
Breo ElliptaFluticasone/Vilanterol	19	$7,671
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	58	$7,499
DuleraMometasone/Formoterol	18	$6,165
SynjardyEmpagliflozin/Metformin Hcl	12	$5,725
Tresiba Flextouch U-100Insulin Degludec	12	$5,539
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	12	$5,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Synjardy	$17	$120,531144 claims
Novo NordiskOzempic	$66	$61,98454 claims
PfizerEliquis	$96	$55,92478 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus	$43	$25,52832 claims
Johnson & JohnsonXarelto	$77	$18,79431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,268 family providers in Iowa.

Other family in Ogden

Stefanie GaticaAnkeny$354K
Aubrey MolgaardAmes$238K
Joan KittenFort Dodge$85K
Megan FergusonPella$82K
Rodney ClarkDes Moines$63K
Jennifer CondonFort Dodge$31K
Karen HunkeAmes$20K
Tonia AckermanWest Des Moines$17K
Chi-Ying SageWaterloo$14K
Amanda GaldiNorth Liberty$14K

See the full list for Iowa →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →